Uniseed
Uniseed is a venture capital firm founded in 2000 and based in Saint Lucia, Australia. Established as a joint initiative between the University of Melbourne and the University of Queensland, Uniseed focuses on investing in technology start-ups, particularly those emerging from its partner research organizations. The firm operates through multiple funds, with its latest, launched in 2015, involving the University of Sydney and CSIRO alongside its founding partners. Uniseed's investment strategy emphasizes long-term partnerships with academic institutions, providing tailored commercialization services that enhance their capabilities. The firm has made over 20 investments, typically ranging from $250,000 to $2.5 million, and has a track record of successful exits. Uniseed's commitment to supporting research commercialization is underscored by its significant contributions to the research ecosystem, which includes nearly $4 billion in research spending and numerous invention disclosures. The firm prioritizes a balanced approach to measuring success, focusing on financial returns, the establishment of viable start-ups, and the enhancement of commercialization processes for its partners.
73 past transactions
Celosia Therapeutics
Series A in 2024
Celosia Therapeutics is a gene therapy company focused on developing innovative treatments for a variety of neurodegenerative diseases, including motor neuron disease, epilepsy, and Alzheimer's disease. By leveraging recent advances in gene therapies and a deeper understanding of the molecular pathways involved in these conditions, Celosia aims to modify the neuronal microenvironment to provide effective therapeutic solutions. The company addresses the significant unmet needs in this space, where traditional treatment options are often limited, thereby offering hope to patients affected by these debilitating disorders.
Kinoxis Therapeutics
Series B in 2024
Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.
Diraq
Series A in 2024
Diraq aims to redefine scalable quantum computing and bring practical commercial applications to the world via billions of qubits on a single chip, compared to the hundreds of qubits that exist today. The company will be an end-to-end quantum computing provider, offering quantum hardware and software as a full stack, cloud accessible service.
Aravax
Series B in 2024
Aravax is an early-stage biotechnology company based in Melbourne, Australia, dedicated to developing a safe and effective treatment for peanut allergy. Founded in May 2015, the company emerged from the acquisition of intellectual property developed by Alfred Health and Monash University. Aravax's innovative approach involves proprietary technology that aims to reset the immune system, allowing patients to tolerate peanuts without experiencing allergic reactions during treatment. The company's focus is on creating vaccines that mitigate the risk of life-threatening responses to peanuts, providing a potential solution for individuals suffering from peanut allergies.
BioScout
Seed Round in 2023
BioScout is a technology company that focuses on detecting and preventing airborne diseases in agricultural settings. It has developed an integrated hardware and software platform specifically designed for farm fields. This patented system employs a combination of air sampling, mapping, and data analytics, utilizing sensors strategically placed throughout the fields. These sensors collect crucial data, which is then relayed to a disease dashboard, providing real-time information and text message alerts regarding high threat levels. By offering proactive disease management solutions, BioScout enables farmers to enhance crop yield and quality, improve spray efficiency, and effectively monitor the spread of diseases.
ResusRight
Seed Round in 2023
ResusRight is a medical device company focused on improving neonatal care through innovative monitoring solutions. The company designs and manufactures devices that provide quantitative feedback on resuscitation techniques, specifically targeting the critical moments during and after birth. By equipping clinicians with advanced monitoring technology, ResusRight aims to enhance the effectiveness of resuscitation efforts for newborns, ultimately working to reduce the risk of death and disability in vulnerable infants. Their commitment to developing these specialized devices reflects a dedication to advancing healthcare practices for newborns in need of immediate medical attention.
Ferronova
Series B in 2023
Ferronova Pty Ltd, established in 2016 and based in Salisbury South, Australia, specializes in manufacturing innovative medical devices for cancer diagnosis and treatment. The company produces surgical oncology tracer devices, utilizing magnetic nanoparticles visible on MRI, enabling non-invasive detection and surgical staging of complex cancers, such as those in the head, neck, and colorectal regions. Ferronova's technology involves magnetic probe-based devices and gamma probes with magnetic tracers, aiding hospitals in accurate and early-stage cancer detection and treatment.
Morse Micro
Series B in 2022
Morse Micro is a wireless integrated circuit solutions company focused on advancing Wi-Fi technology for the Internet of Things (IoT). Founded by industry experts, including original Wi-Fi inventor Prof. Neil Weste, the company has a strong foundation in wireless innovation. Headquartered in Australia, with additional offices in China and the U.S., Morse Micro develops low-power Wi-Fi chips that facilitate connectivity across a wide array of IoT applications, such as surveillance systems, access control, industrial automation, and mobile devices. The company’s expertise and extensive portfolio of intellectual property enable it to create smaller and more cost-effective solutions for clients in the IoT market, enhancing the reach and efficiency of connected devices.
Tiny Bright Things
Seed Round in 2022
Tiny Bright Things is a Melbourne-based company founded in 2020 by Ray Dagastine and Chris Bolton. The company specializes in developing Halo microscopy technology that significantly enhances the imaging and measurement of small or transparent objects. This innovative technology serves both industrial manufacturers and researchers, particularly in fields such as agrichemicals, pharmaceuticals, nanotechnology, and life sciences. By enabling precise imaging and measurement down to the scale of viruses, drug particles, and nanotubes without altering the samples, Tiny Bright Things provides essential tools for accurate analysis at any length scale, thereby supporting advancements in scientific discovery and manufacturing processes.
Analog Quantum Circuits
Seed Round in 2022
Analog Quantum Circuits specializes in the production of analog components for solid-state quantum computers. The company focuses on developing core microwave technologies that enhance the functionality of superconducting quantum devices. By designing and fabricating advanced superconducting elements, Analog Quantum Circuits aims to support scientific advancements within the rapidly evolving quantum computing sector, addressing the increasing demands of this emerging industry.
OccuRx
Series B in 2022
OccuRx is a Melbourne-based biopharmaceutical company founded in 2014 that specializes in developing innovative therapeutic strategies for treating ophthalmic disorders related to retinal fibrosis. The company focuses on creating proprietary small-molecule drugs aimed at addressing the unmet clinical needs for targeted ocular therapies. These therapies are designed to enhance visual acuity and prevent vision loss in patients suffering from inflammatory and degenerative eye diseases. By enabling healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce retinal inflammation, OccuRx aims to improve outcomes for individuals affected by these conditions.
Morse Micro
Series B in 2022
Morse Micro is a wireless integrated circuit solutions company focused on advancing Wi-Fi technology for the Internet of Things (IoT). Founded by industry experts, including original Wi-Fi inventor Prof. Neil Weste, the company has a strong foundation in wireless innovation. Headquartered in Australia, with additional offices in China and the U.S., Morse Micro develops low-power Wi-Fi chips that facilitate connectivity across a wide array of IoT applications, such as surveillance systems, access control, industrial automation, and mobile devices. The company’s expertise and extensive portfolio of intellectual property enable it to create smaller and more cost-effective solutions for clients in the IoT market, enhancing the reach and efficiency of connected devices.
BioScout
Seed Round in 2022
BioScout is a technology company that focuses on detecting and preventing airborne diseases in agricultural settings. It has developed an integrated hardware and software platform specifically designed for farm fields. This patented system employs a combination of air sampling, mapping, and data analytics, utilizing sensors strategically placed throughout the fields. These sensors collect crucial data, which is then relayed to a disease dashboard, providing real-time information and text message alerts regarding high threat levels. By offering proactive disease management solutions, BioScout enables farmers to enhance crop yield and quality, improve spray efficiency, and effectively monitor the spread of diseases.
Forcite Helmet Systems
Series A in 2022
Forcite Helmet Systems Pty Ltd, founded in 2013 and based in Haymarket, Australia, specializes in the manufacture of smart helmets designed to enhance motorcycle safety. The helmets incorporate advanced features such as an integrated camera system, navigation, intercom capabilities, and active noise-cancelling technology. Recognizing the inherent dangers of motorcycling, Forcite aims to significantly improve safety for riders by integrating sensor technology and a proprietary software platform called Forcite Command. By utilizing lightweight carbon fiber in their helmet designs, the company seeks to provide a disruptive solution that addresses the lack of standard safety equipment in motorcycles, ultimately making riding safer and more enjoyable.
Currus Biologics
Series A in 2021
Currus Biologics is a biotechnology company focused on developing CAR-T cell therapies specifically aimed at treating solid tumor cancers. The company specializes in creating bispecific antigen-presenting and T-cell engagers to target and combat various cancer types, including breast, colon, pancreatic, and prostate cancers. By designing chimeric antigen receptors that can effectively kill cancer cells, Currus Biologics aims to provide innovative treatment solutions for patients with solid tumor indications.
Ena Respiratory
Venture Round in 2021
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.
Ena Respiratory
Venture Round in 2021
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.
Kinoxis Therapeutics
Series A in 2020
Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.
Ena Respiratory
Series A in 2020
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.
Ferronova
Series A in 2020
Ferronova Pty Ltd, established in 2016 and based in Salisbury South, Australia, specializes in manufacturing innovative medical devices for cancer diagnosis and treatment. The company produces surgical oncology tracer devices, utilizing magnetic nanoparticles visible on MRI, enabling non-invasive detection and surgical staging of complex cancers, such as those in the head, neck, and colorectal regions. Ferronova's technology involves magnetic probe-based devices and gamma probes with magnetic tracers, aiding hospitals in accurate and early-stage cancer detection and treatment.
Wildlife Drones
Venture Round in 2019
Wildlife Drones Pty. Ltd., founded in 2016 and based in Macquarie, Australia, specializes in designing and developing advanced animal radio-tracking systems utilizing drone technology. The company addresses the challenges faced by wildlife researchers in tracking the movements of radio-tagged animals, a process that can often be labor-intensive and costly when relying on traditional ground methods. By leveraging drones, Wildlife Drones enhances the quality and quantity of radio-tracking data collected, allowing for improved monitoring of endangered species, tracking of invasive species, and management of livestock in remote areas. This innovative approach provides wildlife researchers, conservationists, and environmental consultants with more effective tools to understand animal movements and minimize environmental impact.
Aurtra
Seed Round in 2019
Aurtra Pty Ltd., established in 2016 and headquartered in Corinda, Australia, specializes in cloud-based asset management solutions for power distribution networks. The company offers a dashboard that provides real-time, fleet-wide analysis of transformers, enabling asset managers and engineers to extend transformer life, reduce capital costs, and make informed decisions regarding maintenance, replacement, and load management. Aurtra's technology, built upon a decade of research from The University of Queensland, helps mitigate catastrophic failures and improves risk management in the power distribution industry.
OccuRx
Series A in 2019
OccuRx is a Melbourne-based biopharmaceutical company founded in 2014 that specializes in developing innovative therapeutic strategies for treating ophthalmic disorders related to retinal fibrosis. The company focuses on creating proprietary small-molecule drugs aimed at addressing the unmet clinical needs for targeted ocular therapies. These therapies are designed to enhance visual acuity and prevent vision loss in patients suffering from inflammatory and degenerative eye diseases. By enabling healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce retinal inflammation, OccuRx aims to improve outcomes for individuals affected by these conditions.
Morse Micro
Series A in 2019
Morse Micro is a wireless integrated circuit solutions company focused on advancing Wi-Fi technology for the Internet of Things (IoT). Founded by industry experts, including original Wi-Fi inventor Prof. Neil Weste, the company has a strong foundation in wireless innovation. Headquartered in Australia, with additional offices in China and the U.S., Morse Micro develops low-power Wi-Fi chips that facilitate connectivity across a wide array of IoT applications, such as surveillance systems, access control, industrial automation, and mobile devices. The company’s expertise and extensive portfolio of intellectual property enable it to create smaller and more cost-effective solutions for clients in the IoT market, enhancing the reach and efficiency of connected devices.
Agerris
Seed Round in 2019
Agerris Pty Ltd, established in 2005 and based in Chippendale, Australia, specializes in designing and manufacturing modular robotics for the agricultural industry. The company's flagship product, Swagbot, is a modular robot that autonomously monitors and addresses weed issues, detects food, herds livestock, and assesses crops using computer vision. Additionally, Agerris develops an AI-based platform, Digital Farmhand, which enables farm machinery to detect and assess weeds, count individual fruit, nuts, crops, and animals. The company's products cater to various applications, including tree crop and row crop automation, intelligent spraying, livestock monitoring, and fruit and crop detection.
Forcite Helmet Systems
Seed Round in 2019
Forcite Helmet Systems Pty Ltd, founded in 2013 and based in Haymarket, Australia, specializes in the manufacture of smart helmets designed to enhance motorcycle safety. The helmets incorporate advanced features such as an integrated camera system, navigation, intercom capabilities, and active noise-cancelling technology. Recognizing the inherent dangers of motorcycling, Forcite aims to significantly improve safety for riders by integrating sensor technology and a proprietary software platform called Forcite Command. By utilizing lightweight carbon fiber in their helmet designs, the company seeks to provide a disruptive solution that addresses the lack of standard safety equipment in motorcycles, ultimately making riding safer and more enjoyable.
Wildlife Drones
Seed Round in 2019
Wildlife Drones Pty. Ltd., founded in 2016 and based in Macquarie, Australia, specializes in designing and developing advanced animal radio-tracking systems utilizing drone technology. The company addresses the challenges faced by wildlife researchers in tracking the movements of radio-tagged animals, a process that can often be labor-intensive and costly when relying on traditional ground methods. By leveraging drones, Wildlife Drones enhances the quality and quantity of radio-tracking data collected, allowing for improved monitoring of endangered species, tracking of invasive species, and management of livestock in remote areas. This innovative approach provides wildlife researchers, conservationists, and environmental consultants with more effective tools to understand animal movements and minimize environmental impact.
PERKii
Venture Round in 2018
PERKii is a producer of innovative probiotic beverages designed to deliver live and protected probiotics in a refreshing, water-based drink. Each serving contains only 26 calories and minimal sugar, making it a healthier choice for consumers. Utilizing Progel™ technology, developed by scientists at The University of Queensland, PERKii encapsulates probiotics in microgels that withstand stomach acid, ensuring their effectiveness in promoting gut health and immunity. This unique technology sets PERKii apart from traditional probiotic drinks, enhancing the overall health benefits while providing a delicious taste experience. The company aims to support consumers in managing weight and improving their overall well-being through its carefully crafted beverages.
Exonate
Seed Round in 2018
Exonate Limited is a privately held biotech company founded in 2013 and based in Duxford, United Kingdom, with a research and development laboratory in Nottingham. The company specializes in the discovery and development of small molecule drugs that target alternative messenger RNA splicing, particularly in the field of ophthalmology. Exonate's lead program focuses on diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD), significant causes of vision loss. The company has developed a pipeline of novel small molecule inhibitors, known as SPHINXes, which selectively inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the modulation of serine/threonine-protein kinase 1 (SRPK1)-mediated splicing. These inhibitors have shown promising efficacy in preclinical models as topical agents for treating these retinal disorders. Exonate is backed by a strong scientific foundation and leadership team, with connections to academic expertise at the University of Nottingham. The company is advancing its drug candidates through regulatory studies aimed at clinical evaluation.
Q-Sera
Venture Round in 2018
Q-Sera Pty Ltd is an Australian biotechnology company that specializes in the development of advanced blood collection tubes utilizing the coagulant properties of snake venom-derived proteins. The company has harnessed the potent clotting capabilities of components found in snake venom, particularly from species like the Australian Taipan, to create blood collection tubes that enable rapid production of high-quality serum. This innovative technology enhances laboratory efficiency, clinical diagnosis, and patient care by facilitating quicker coagulation of blood samples. Q-Sera's products are manufactured using modified cell lines and standard pharmaceutical processes, ensuring reliability and effectiveness in biochemical analysis of blood samples. The company's focus on leveraging unique natural resources positions it at the forefront of advancements in clinical and laboratory practices.
Kinoxis Therapeutics
Seed Round in 2018
Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.
Nexgen Plants
Venture Round in 2018
Nexgen Plants is an innovative plant trait company focused on developing non-genetically modified (non-GM) solutions to enhance agricultural productivity and resilience against various challenges. The company specializes in creating disease-resistant plant breeds by leveraging a proprietary transformation technique that identifies key elements in native DNA. This approach enables the development of crops that are resistant to viruses and fungi, as well as traits such as salt tolerance and increased anthocyanin content. Nexgen Plants aims to produce the next generation of globally valued crops for food, fiber, energy, and ornamental purposes, ultimately helping agriculture-dependent communities improve their returns and adapt to emerging opportunities.
Certa
Seed Round in 2018
Certa is a technology company that specializes in managing third-party relationships for businesses. Its core product is an automated SaaS platform designed to streamline various aspects of third-party lifecycle management, including onboarding, due diligence, risk mitigation, and ongoing monitoring. This platform enables companies to efficiently manage the operational risks, compliance issues, and overall workflow associated with their third-party interactions globally from a single location.
Certa Therapeutics
Grant in 2018
Certa Therapeutics, established in 2017 and headquartered in Melbourne, Australia, is a biotechnology company specializing in the development of precision medicines for fibrotic diseases, with a primary focus on kidney disorders. The company employs genetic analysis to identify patients at risk of developing kidney fibrosis, a precursor to end-stage kidney failure. Certa's drug pipeline targets a key receptor driving kidney fibrosis, aiming to halt or reverse the scarring process and prevent the need for dialysis or transplantation. Currently in the clinical stage, the company's mission is to transform the treatment landscape for fibrotic diseases by enabling early intervention and improving patient outcomes.
Kinoxis Therapeutics
Venture Round in 2018
Kinoxis Therapeutics is an Australian early-stage biotechnology company focused on advancing novel therapeutic compounds licensed from the University of Sydney. Its primary objective is to develop treatments for substance use disorders and other central nervous system (CNS) conditions. The company's lead candidate has shown promising anti-addictive and prosocial effects in various animal models and is currently undergoing pre-clinical testing. Kinoxis aims to address the growing need for effective therapies in this area, with a particular focus on opioid withdrawal, methamphetamine use disorder, and nicotine withdrawal.
Cardihab
Seed Round in 2017
Cardihab Pty Ltd., established in 2016 and based in Fortitude Valley, Australia, specializes in digital cardiac rehabilitation solutions. It offers a cloud-based portal and smartphone app, enabling clinicians to manage patient data, track goals, and connect to sensors. This allows for remote cardiac rehabilitation, reducing the need for frequent clinic visits and making the process more convenient and flexible for patients.
Brisbane Materials
Series B in 2017
Brisbane Materials Technology Pty Ltd. is an Australian manufacturer specializing in anti-reflective coatings, primarily for lighting and solar power applications. Founded in 2005 and based in St Lucia, the company emerged from the University of Queensland and has leveraged significant investment and technology development over the years. Brisbane Materials focuses on producing innovative optical coatings, including low-cost, wide-area anti-reflective coatings made from porous silica and other materials. These coatings are manufactured using a patented technology that allows for the creation of an inorganic layer from a liquid precursor at room temperature and atmospheric pressure. This process not only enhances the efficiency of solar panel covers for photovoltaic and solar thermal systems but also offers a cost-effective solution for lighting applications. As a subsidiary of XeroCoat, Brisbane Materials aims to expand its unique coating technology to a broader range of materials and applications in the future.
QUE Oncology
Series A in 2017
QUE Oncology, Inc. is a biopharmaceutical company that specializes in drug development and therapies for various types of cancer, including breast and prostate cancer. Founded in 2013 and based in Atlanta, Georgia, QUE Oncology was established through a collaboration between Emory University and The University of Queensland's research commercialization entity, UniQuest. The company focuses on licensing intellectual property derived from significant research discoveries at both institutions. Its lead drug candidate, Q-122, is a non-hormonal small molecule currently in Phase 1b clinical development, specifically targeting hot flashes in women undergoing anti-estrogen therapy for breast cancer. QUE Oncology also explores additional cancer research initiatives aimed at addressing unmet medical needs related to prostate cancer, melanoma, and cancer-related pain.
Ena Respiratory
Venture Round in 2017
Ena Respiratory Pty Ltd is a biotechnology company based in Melbourne, Australia, focused on transforming the treatment and prevention of respiratory infections. Incorporated in 2020, the company develops synthetic innate immunomodulators aimed at preventing respiratory viral and bacterial infections. Ena Respiratory specializes in novel Toll-like receptor 2 (TLR2) receptor agonists that activate the innate immune system within the respiratory tract. This targeted approach allows for topical delivery to the airways, effectively preventing the dissemination of infections to the lungs. The company's innovations aim to enhance the effectiveness of vaccines and safeguard patients with pre-existing lung conditions from critical complications related to respiratory diseases.
Smart Sparrow
Series C in 2017
Smart Sparrow is an e-learning platform that facilitates the creation of interactive and adaptive courseware for a variety of subjects, including digital literacy, computer sciences, finance, and soft skills. Founded in 2010 by Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson, the company is headquartered in Surry Hills, Australia, with an additional office in San Francisco, California. Smart Sparrow's platform features a dynamic, drag-and-drop authoring tool compatible with any web browser, allowing educators to design personalized learning experiences. This tool enables real-time collaboration and provides access to pre-made templates, streamlining the course creation process. The company serves a diverse range of institutions both locally and internationally.
Exonate
Angel Round in 2016
Exonate Limited is a privately held biotech company founded in 2013 and based in Duxford, United Kingdom, with a research and development laboratory in Nottingham. The company specializes in the discovery and development of small molecule drugs that target alternative messenger RNA splicing, particularly in the field of ophthalmology. Exonate's lead program focuses on diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD), significant causes of vision loss. The company has developed a pipeline of novel small molecule inhibitors, known as SPHINXes, which selectively inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the modulation of serine/threonine-protein kinase 1 (SRPK1)-mediated splicing. These inhibitors have shown promising efficacy in preclinical models as topical agents for treating these retinal disorders. Exonate is backed by a strong scientific foundation and leadership team, with connections to academic expertise at the University of Nottingham. The company is advancing its drug candidates through regulatory studies aimed at clinical evaluation.
PERKii
Venture Round in 2016
PERKii is a producer of innovative probiotic beverages designed to deliver live and protected probiotics in a refreshing, water-based drink. Each serving contains only 26 calories and minimal sugar, making it a healthier choice for consumers. Utilizing Progel™ technology, developed by scientists at The University of Queensland, PERKii encapsulates probiotics in microgels that withstand stomach acid, ensuring their effectiveness in promoting gut health and immunity. This unique technology sets PERKii apart from traditional probiotic drinks, enhancing the overall health benefits while providing a delicious taste experience. The company aims to support consumers in managing weight and improving their overall well-being through its carefully crafted beverages.
MetaBloQ
Seed Round in 2016
MetaBloQ is a biotechnology company dedicated to the development of innovative drugs aimed at treating various types of cancer, including triple-negative breast cancer, prostate cancer, and melanoma. The company focuses on targeting specific metabolic processes in cancer cells, allowing for therapies that minimize toxicity to healthy, non-cancerous cells. This approach aims to provide patients with safer, more effective, and better-tolerated treatment options in the fight against cancer.
OccuRx
Venture Round in 2015
OccuRx is a Melbourne-based biopharmaceutical company founded in 2014 that specializes in developing innovative therapeutic strategies for treating ophthalmic disorders related to retinal fibrosis. The company focuses on creating proprietary small-molecule drugs aimed at addressing the unmet clinical needs for targeted ocular therapies. These therapies are designed to enhance visual acuity and prevent vision loss in patients suffering from inflammatory and degenerative eye diseases. By enabling healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce retinal inflammation, OccuRx aims to improve outcomes for individuals affected by these conditions.
ProGel
Series B in 2014
ProGel Pty Ltd, founded in 2009 and based in Brisbane, Australia, specializes in the development and manufacture of innovative microencapsulation technology. The company emerged from research at the University of Queensland, focusing on a method that allows for the encapsulation of active ingredients for use in foods, cosmetics, and pharmaceuticals. ProGel's calcium alginate microgels are designed to withstand gastric conditions, enabling the effective delivery of high-value additives in functional foods like probiotic drinks and omega-3 enriched products. This technology not only ensures that the encapsulated ingredients remain undetectable to consumers but also provides a cost-effective solution for manufacturers. ProGel is positioned to tap into rapidly growing multi-billion dollar markets, with targeted sectors experiencing growth rates exceeding 10% annually.
TenasiTech
Angel Round in 2014
TenasiTech specializes in the development of composite polymers tailored for various industries, including engineering, sporting, automotive, and construction. The company's polymer products are characterized by their mechanical strength and resistance to creep, compressive set, chemicals, and thermal instability. These attributes enable businesses to enhance the durability and performance of engineering thermoplastics, making them more resilient to surface damage. Through its innovative approach, TenasiTech addresses the specific needs of its clients across multiple sectors, providing advanced materials that contribute to improved product longevity and reliability.
Spinifex Pharmaceuticals
Series C in 2014
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech
Venture Round in 2013
Hatchtech is an Australian company focused on developing a proprietary technology platform aimed at creating low-toxicity pest control products. The company's patented technology offers a novel mode of action that effectively blocks the hatching of pest species' eggs, making it applicable for managing ectoparasites and other egg-laying pests affecting humans, animals, crops, and built environments. Hatchtech also provides a specialized pharmaceutical product that delivers a single-dose, topical treatment designed to eliminate head lice infestations by killing both the lice and their eggs in one application. Through its innovative approaches, Hatchtech seeks to advance pest control solutions with reduced environmental impact.
Nexgen Plants
Series A in 2013
Nexgen Plants is an innovative plant trait company focused on developing non-genetically modified (non-GM) solutions to enhance agricultural productivity and resilience against various challenges. The company specializes in creating disease-resistant plant breeds by leveraging a proprietary transformation technique that identifies key elements in native DNA. This approach enables the development of crops that are resistant to viruses and fungi, as well as traits such as salt tolerance and increased anthocyanin content. Nexgen Plants aims to produce the next generation of globally valued crops for food, fiber, energy, and ornamental purposes, ultimately helping agriculture-dependent communities improve their returns and adapt to emerging opportunities.
Hydrexia
Series B in 2013
Hydrexia is an Australian company that has successfully designed, built, and tested systems that stores hydrogen in solid form, based on a proprietary magnesium alloy.
TenasiTech
Grant in 2012
TenasiTech specializes in the development of composite polymers tailored for various industries, including engineering, sporting, automotive, and construction. The company's polymer products are characterized by their mechanical strength and resistance to creep, compressive set, chemicals, and thermal instability. These attributes enable businesses to enhance the durability and performance of engineering thermoplastics, making them more resilient to surface damage. Through its innovative approach, TenasiTech addresses the specific needs of its clients across multiple sectors, providing advanced materials that contribute to improved product longevity and reliability.
Q-Sera
Series A in 2012
Q-Sera is an anti-hair loss therapy platform.
Hatchtech
Venture Round in 2012
Hatchtech is an Australian company focused on developing a proprietary technology platform aimed at creating low-toxicity pest control products. The company's patented technology offers a novel mode of action that effectively blocks the hatching of pest species' eggs, making it applicable for managing ectoparasites and other egg-laying pests affecting humans, animals, crops, and built environments. Hatchtech also provides a specialized pharmaceutical product that delivers a single-dose, topical treatment designed to eliminate head lice infestations by killing both the lice and their eggs in one application. Through its innovative approaches, Hatchtech seeks to advance pest control solutions with reduced environmental impact.
Spinifex Pharmaceuticals
Series B in 2011
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Verva Pharmaceuticals
Venture Round in 2011
Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need. Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
Smart Sparrow
Series A in 2011
Smart Sparrow is an e-learning platform that facilitates the creation of interactive and adaptive courseware for a variety of subjects, including digital literacy, computer sciences, finance, and soft skills. Founded in 2010 by Ariel Shoham, Dror Ben-Haim, Shaowei Ho, and Zack Belinson, the company is headquartered in Surry Hills, Australia, with an additional office in San Francisco, California. Smart Sparrow's platform features a dynamic, drag-and-drop authoring tool compatible with any web browser, allowing educators to design personalized learning experiences. This tool enables real-time collaboration and provides access to pre-made templates, streamlining the course creation process. The company serves a diverse range of institutions both locally and internationally.
Otifex
Series A in 2010
Otifex Therapeutics Pty Ltd is an Australian specialty pharmaceutical company focused on developing innovative treatments for Otitis Media with Effusion (OME), a common cause of acquired hearing loss in children. Currently, the standard treatment for OME often involves surgical insertion of grommets to regulate middle ear pressure, with no effective non-invasive alternatives available. Otifex is pioneering a novel nasal spray aimed at facilitating the natural equalization of middle ear pressure, potentially allowing OME to resolve without surgery. The company also produces nasal spray products and tablets based on betahistine, which is known for its use in treating Meniere's Disease and Vestibular Vertigo. These formulations are designed to aid in the clearance of fluid from the middle ear, offering a promising solution for children suffering from OME.
Hatchtech
Venture Round in 2010
Hatchtech is an Australian company focused on developing a proprietary technology platform aimed at creating low-toxicity pest control products. The company's patented technology offers a novel mode of action that effectively blocks the hatching of pest species' eggs, making it applicable for managing ectoparasites and other egg-laying pests affecting humans, animals, crops, and built environments. Hatchtech also provides a specialized pharmaceutical product that delivers a single-dose, topical treatment designed to eliminate head lice infestations by killing both the lice and their eggs in one application. Through its innovative approaches, Hatchtech seeks to advance pest control solutions with reduced environmental impact.
BT Imaging
Series A in 2010
BT Imaging is a leading manufacturer of electrical-inspection equipment designed for the photovoltaic manufacturing industry. The company specializes in luminescence-based inspection systems that facilitate the design and production of silicon blocks, solar wafers, and solar cells. Its tools are utilized for research, product and process development, as well as production manufacturing inspection and quality control. By enhancing inspection and quality assurance processes, BT Imaging's systems enable clients to improve factory yields and increase the efficiency of solar cells. The company plays a vital role in advancing solar technology, supporting the growth of sustainable energy solutions.
ProGel
Series A in 2010
ProGel Pty Ltd, founded in 2009 and based in Brisbane, Australia, specializes in the development and manufacture of innovative microencapsulation technology. The company emerged from research at the University of Queensland, focusing on a method that allows for the encapsulation of active ingredients for use in foods, cosmetics, and pharmaceuticals. ProGel's calcium alginate microgels are designed to withstand gastric conditions, enabling the effective delivery of high-value additives in functional foods like probiotic drinks and omega-3 enriched products. This technology not only ensures that the encapsulated ingredients remain undetectable to consumers but also provides a cost-effective solution for manufacturers. ProGel is positioned to tap into rapidly growing multi-billion dollar markets, with targeted sectors experiencing growth rates exceeding 10% annually.
Manjrasoft
Venture Round in 2009
Manjrasoft Pty. Ltd., founded in 2008 and headquartered in Melbourne, Australia, specializes in commercializing advanced grid and cloud computing technologies. The company offers Aneka, a development and management platform that facilitates rapid application development and efficient workload distribution. This platform serves various sectors, including engineering, entertainment and gaming, life sciences, and finance. Manjrasoft provides a range of solutions, such as distributed 3D rendering with Autodesk Maya, educational tools, and cloud computing consultancy services. The company's offerings are designed to enhance the performance and efficiency of software applications that require significant computational power by enabling them to operate across multiple networked computers and servers.
Verva Pharmaceuticals
Venture Round in 2009
Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need. Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
Fibrotech Therapeutics
Series A in 2008
Fibrotech Therapeutics is a biopharmaceutical company based in Wonga Park, Australia, focused on developing novel drug candidates aimed at treating fibrosis associated with various chronic conditions. Established in 2006, the company is dedicated to addressing unmet medical needs in diseases such as diabetic nephropathy, kidney disorders, heart failure, pulmonary fibrosis, and arthritis. Through its innovative approach, Fibrotech Therapeutics seeks to provide effective therapeutic options for patients suffering from these debilitating conditions.
Spinifex Pharmaceuticals
Series A in 2008
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
TenasiTech
Seed Round in 2008
TenasiTech specializes in the development of composite polymers tailored for various industries, including engineering, sporting, automotive, and construction. The company's polymer products are characterized by their mechanical strength and resistance to creep, compressive set, chemicals, and thermal instability. These attributes enable businesses to enhance the durability and performance of engineering thermoplastics, making them more resilient to surface damage. Through its innovative approach, TenasiTech addresses the specific needs of its clients across multiple sectors, providing advanced materials that contribute to improved product longevity and reliability.
BT Imaging
Series A in 2008
BT Imaging is a leading manufacturer of electrical-inspection equipment designed for the photovoltaic manufacturing industry. The company specializes in luminescence-based inspection systems that facilitate the design and production of silicon blocks, solar wafers, and solar cells. Its tools are utilized for research, product and process development, as well as production manufacturing inspection and quality control. By enhancing inspection and quality assurance processes, BT Imaging's systems enable clients to improve factory yields and increase the efficiency of solar cells. The company plays a vital role in advancing solar technology, supporting the growth of sustainable energy solutions.
Pepfactants
Series B in 2007
Pepfactants has developed a new way to break apart industrial emulsions, including those found in oil & gas operations, environmental remediation and other manufacturing processes. The company has discovered a chemical additive for demulsify the emulsions, where the additive is cheaper than many alternatives, and withstands extreme levels of salt and other contaminants. The chemical is readily available today as it is used for other, unrelated applications.
Fultec Semiconductor
Series C in 2006
Fultec Semiconductor is a circuit protection semiconductor company based in Mountain View, California, founded in 2001. It specializes in producing transient blocking devices designed to safeguard telecommunication and data communication systems from over-voltage and over-current conditions. The company's products provide extensive bandwidth circuit protection against various electrical threats, including lightning strikes, power induction, power cross, and short circuit events. Fultec's offerings find applications across multiple sectors such as telecommunications, data communications, sensors, automotive, and power distribution. As of 2008, Fultec Semiconductor operates as a subsidiary of Bourns, Inc.
OPAL Therapeutics
Series A in 2005
OPAL Therapeutics Pty Limited operates as an immunotherapy development company in Australia. It develops therapies for the treatment of human immunodeficiency virus, Hepatitis C, and chronic infection. OPAL Therapeutics Pty Limited was incorporated in 2005 and is based in Melbourne, Australia.
Spinifex Pharmaceuticals
Series A in 2005
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech
Venture Round in 2005
Hatchtech is an Australian company focused on developing a proprietary technology platform aimed at creating low-toxicity pest control products. The company's patented technology offers a novel mode of action that effectively blocks the hatching of pest species' eggs, making it applicable for managing ectoparasites and other egg-laying pests affecting humans, animals, crops, and built environments. Hatchtech also provides a specialized pharmaceutical product that delivers a single-dose, topical treatment designed to eliminate head lice infestations by killing both the lice and their eggs in one application. Through its innovative approaches, Hatchtech seeks to advance pest control solutions with reduced environmental impact.
QRxPharma
Series A in 2002
QRxPharma Limited is an Australian-based pharmaceutical company focused on the research, development, and commercialization of biopharmaceutical products, particularly in pain management and abuse prevention. The company has developed a Dual Opioid platform technology, which is a patented fixed-ratio combination of morphine and oxycodone aimed at improving pain relief. Additionally, QRxPharma is known for its proprietary Stealth Beadlets technology, designed to deter drug abuse in solid dosage forms. The company's product portfolio includes both late and early-stage clinical candidates, with an emphasis on enhancing the clinical utility of approved compounds. QRxPharma has engaged in strategic partnerships for the commercialization of its lead product, immediate release MOXDUO, in various regions including the US, Canada, Australia, and South Africa. Although QRxPharma has seen changes in its operational status, it remains focused on advancing innovative solutions in pain management and abuse prevention.
Wedgetail Communications
Seed Round in 2001
Wedgetail Communications develops security technology for all classes of network devices.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.